Hori S

No ORCID on file · 2 papers in corpus

rct 2026

Linzagolix, with and without add-back therapy, in women with endometriosis-associated pain: results from EDELWEISS 6, a double-blind randomized extension and withdrawal study

Human reproduction open ·doi:10.1093/hropen/hoag030

STUDY QUESTION: Was the efficacy of linzagolix, observed at 6 months in women with endometriosis-associated pain, maintained when administered for an additional 6 months? SUMMARY ANSWER: Efficacy from this extension study complements the r…

rct 2025

Linzagolix with and without hormonal add-back therapy for symptomatic uterine fibroids: PRIMROSE 1 & 2 long-term extension and withdrawal study

Fertility and sterility ·doi:10.1016/j.fertnstert.2025.06.016

OBJECTIVE: To evaluate whether oral linzagolix administered once daily for up to 52 weeks (extension study) at a dose of 100 mg or 200 mg with or without hormonal add-back therapy (ABT) (1.0 mg estradiol; 0.5 mg norethisterone acetate) can …